Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

cardiovascular · Mechanism Report

Does estrogen loss after menopause reduce LDL clearance and raise LDL cholesterol?

Menopause-related estrogen loss likely contributes to higher LDL cholesterol and ApoB-containing particles by slowing LDL clearance.

PlausibleOctober 2, 20266 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Loss of estrogen after menopause can reduce hepatic LDL receptor activity and increase circulating LDL cholesterol and ApoB-containing particles.

laying out figure…
0 of 4 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says that after menopause, lower estrogen can reduce hepatic LDL receptor activity, which would lessen removal of LDL particles from circulation. The conclusion frames this as biologically plausible and consistent with human kinetic data showing slower LDL-apoB clearance and higher LDL-C and apoB around the menopausal transition.

Verified conclusion

Menopause is accompanied by a rise in atherogenic lipoproteins, and estrogen loss is a biologically credible contributor through impaired LDL particle clearance. For a 53-year-old woman, this is particularly relevant because the late perimenopausal/early postmenopausal period is when LDL-C and apoB tend to increase.

Clinical and kinetic evidence

  • In the SWAN longitudinal cohort, LDL-C increased principally during late perimenopause and early postmenopause. Early postmenopausal women had higher odds of LDL-C ≥130 mg/dL than premenopausal women (OR 2.1, 95% CI 1.5–2.9), and apoB rose around the final menstrual period independently of age.
  • A metabolic tracer study found a 32% lower LDL-apoB fractional catabolic rate in postmenopausal women, with a larger LDL particle pool attributed mainly to slower clearance rather than increased production.
  • Estradiol studies provide complementary directionality: in 79 postmenopausal women, oral estradiol increased LDL-apoB clearance by 18% and reduced LDL-C by 19%. Another oral study reported a 36% increase in LDL catabolism with a 14% LDL-C reduction. Transdermal estradiol reduced LDL-C by 9%, with only a small nonsignificant average clearance change.

Mechanistic interpretation

  • Hepatic LDL receptors are central to removal of LDL-apoB particles. Experimental evidence indicates estradiol can increase LDLR promoter activity through ERα/Sp1 signaling and may preserve surface LDL receptors by GPER-mediated limitation of PCSK9-dependent receptor internalization and degradation.
  • Loss of these estrogen-responsive pathways would be expected to reduce receptor-mediated LDL uptake, increasing LDL-C and apoB-containing LDL particle burden.

Bottom line

  • The claim is plausible with moderate confidence: menopause-associated estrogen loss likely contributes to slower LDL-apoB clearance and higher LDL-C/apoB, although direct measurement of reduced hepatic LDL-receptor activity across human menopause has not been reported.

References

  1. Emergence of the Metabolic Syndrome with Menopause — academic.oup.com ↗
  2. Mechanisms Regulating LDL Metabolism in Subjects on Peroral and Transdermal Estrogen Replacement Therapy | Arteriosclerosis, Thrombosis, and Vascular Biology — ahajournals.org ↗
  3. Requirement of Sp1 and Estrogen Receptor α Interaction in 17β ... — academic.oup.com ↗
  4. Frontiers | 17β-Estradiol Inhibits PCSK9-Mediated LDLR Degradation Through GPER/PLC Activation in HepG2 Cells — frontiersin.org ↗
  5. Sex Differences in Lipid and Lipoprotein Metabolism - PMC - NIH — pmc.ncbi.nlm.nih.gov ↗
  6. TRL, IDL, and LDL Apolipoprotein B-100 and HDL Apolipoprotein A-I Kinetics as a Function of Age and Menopausal Status | Arteriosclerosis, Thrombosis, and Vascular Biology — ahajournals.org ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible4 sourcesCan LDLR rs688 CT reduce LDL receptor splicing efficiency and LDL clearance?→Plausible6 sourcesDoes oxidized LDL promote foam-cell formation and early atherosclerotic plaque development?→